Neurofibromatosis 2 - 25 Studies Found
Completed |
: An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors : Neurofibromatosis 2 : 2002-01-30 : Device: Penetrating auditory brainstem implant |
Completed |
: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients : Neurofibromatosis 2 : 2011-11-30 : Drug: RAD001 10 mg per os / day or 05mg per os / day with 12 month |
Suspended |
: PTC299 for Treatment of Neurofibromatosis Type 2 : Neurofibromatosis 2 : 2009-05-28 : Drug: PTC299 PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until t |
Recruiting |
: AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas :
: 2016-07-07 : Drug: AZD2014 |
Completed |
: Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 : Neurofibromatosis 2 : 1999-10-18 : Device: Multichannel Auditory Brain Stem Implant |
Recruiting |
: Resiliency Training for Patients With NF2 Via Videoconferencing With Skype : Neurofibromatosis 2 : 2016-06-21 :
|
Completed |
: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 : Neurofibromatosis Type II : 2011-08-17 : Drug: Everolimus (RAD001) , Afinitor® Everolimus will be provided by Novartis. Everolimus is formul |
Completed |
: Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors :
: 2009-09-03 : Drug: Lapatinib Lapatinib is dosed according to age. Lapat |
Active, not recruiting |
: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas :
: Drug: Bevacizumab Treatment will be administered on an out |
Recruiting |
: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors :
: 2016-10-13 : Drug: Icotinib Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Tot |